Paris - Delayed Quote EUR

Quantum Genomics Société Anonyme (ALQGC.PA)

0.1292 +0.0024 (+1.89%)
At close: 5:25 PM GMT+2
Loading Chart for ALQGC.PA
DELL
  • Previous Close 0.1268
  • Open 0.1268
  • Bid --
  • Ask --
  • Day's Range 0.1190 - 0.1346
  • 52 Week Range 0.0804 - 0.1950
  • Volume 97,834
  • Avg. Volume 115,696
  • Market Cap (intraday) 4.491M
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8000
  • Earnings Date Mar 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 10.00

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.

www.quantum-genomics.com

3

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: ALQGC.PA

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ALQGC.PA
21.89%
CAC 40
7.23%

1-Year Return

ALQGC.PA
1.37%
CAC 40
7.39%

3-Year Return

ALQGC.PA
96.74%
CAC 40
29.25%

5-Year Return

ALQGC.PA
97.57%
CAC 40
45.53%

Compare To: ALQGC.PA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ALQGC.PA

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    4.41M

  • Enterprise Value

    -2.96M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.29

  • Price/Book (mrq)

    1.21

  • Enterprise Value/Revenue

    -4.89

  • Enterprise Value/EBITDA

    0.10

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -14.31%

  • Return on Equity (ttm)

    -156.81%

  • Revenue (ttm)

    19.8k

  • Net Income Avi to Common (ttm)

    -3.17M

  • Diluted EPS (ttm)

    -0.8000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.55M

  • Total Debt/Equity (mrq)

    622.18%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ALQGC.PA

Analyst Price Targets

10.00
10.00 Average
0.1292 Current
10.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: ALQGC.PA

People Also Watch